Document:

Third Amendment to Patent Security Agreement

 Exhibit 10.4 
 Portions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 406 under the Securities Act of 1933. Such
omissions are designated as ***. 
 THIRD AMENDMENT TO PATENT SECURITY AGREEMENT 
 THIS THIRD AMENDMENT TO PATENT SECURITY AGREEMENT (the “Third Amendment”) is entered into as of this 10th day of May, 2007
by and between UNIGENE LABORATORIES, INC., a Delaware corporation, having its principal place of business at 110 Little Falls Road, Fairfield, New Jersey 07004 (the “Company”), and JAYNJEAN LEVY FAMILY LIMITED
PARTNERSHIP, a Delaware limited partnership (the “Secured Party”). 
 WITNESSETH: 
 WHEREAS, the Company and Jay Levy, a resident of New Jersey (“Levy”), are parties to that certain Patent Security Agreement,
dated as of March 13, 2001 (as amended, restated, modified or otherwise supplemented from time to time, the “Agreement”), pursuant to which the Company granted Levy a security interest in certain of its patents and
patent applications to secure payment by the Company of the Obligations (as defined in the Agreement); 
 WHEREAS, the Company and Levy
entered into that certain First Amendment to Patent Security Agreement, dated as of May 29, 2001 (the “First Amendment”), to add a certain patent application to the Collateral (as defined in the Agreement); 

WHEREAS, the Company and Levy entered into that certain Second Amendment to Patent Security Agreement, dated as of November 26, 2002 (the
“Second Amendment”), to reference to patent license rights granted to Upsher-Smith Laboratories, Inc.; 
 WHEREAS, on
February 15, 2005, Levy assigned to Secured Party the promissory notes detailed on Schedule A hereto, and by virtue of such assignment (the “Assignment”), Levy’s interest pursuant to the Agreement was
assigned, in accordance with Section 11 of the Agreement, to Secured Party; 
 WHEREAS, the Company hereby acknowledges and agrees that
due to the Assignment, Secured Party has, and Levy no longer has, rights and obligations under the Agreement; 
 WHEREAS, the Company is now
repaying some of the outstanding Obligations due and payable to Secured Party; 

 WHEREAS, in connection with, and in consideration of, such repayment, the Company is restructuring the
remaining outstanding Obligations and consolidating all of the principal and interest currently outstanding on those certain promissory notes payable to Secured Party, listed on Schedule B hereto, into one secured promissory note (the
“Partnership Note”), dated as of the date hereof, payable to Secured Party in the new original principal amount of $7,418,803; and 
 WHEREAS, in connection therewith, the Company and Secured Party wish to contemporaneously enter into this Third Amendment to secure the Partnership Note instead of the notes detailed on Schedule A hereto;
provided, that the Company and Secured Party each agree that neither the Partnership Note nor this Third Amendment represents, evidences or documents a novation of said notes, but rather represents, evidences and documents the continuation of
all obligations and liabilities of every kind and nature of the Company outstanding thereunder that exist as of the date hereof. 
 NOW,
THEREFORE, in consideration of the premises, the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Definitions. All capitalized terms used and not otherwise defined herein have the respective meanings given to them in the Agreement, the First Amendment or the
Second Amendment. 
 2. Amendments. 
 2.1.
Sections 1.2 and 1.3 of the Agreement shall be amended and restated to read in their entirety as follows: 
  

	 	“1.2	“Event of Default” shall mean: 

  

	 	(a)	an “Event of Default” as defined in the Partnership Note; 

  

	 	(b)	any event of default specified in any Future Note; and 

  

	 	(c)	any material breach of any representation made by the Company in Section 4 hereof. 

  

	 	1.3	“Obligations” shall mean all indebtedness, obligations and liabilities of every kind and nature of the Company to the Secured Party now or hereafter existing under or
arising out of or in connection with the Partnership Note, all Future Notes (if any), and this Agreement and all extensions, amendments or renewals hereof or thereof, whether for principal, premium, interest or fees, and all or any portion of such
indebtedness, obligations or liabilities that are paid to the extent all or any part of such payment is avoided or recovered directly or indirectly from the Secured Party as a preference, fraudulent transfer or otherwise.”

  

 - 2 - 

 2.2. Section 3 of the Agreement shall be amended and restated to read in its entirety as follows:

 “3. Release and Satisfaction. 
 3.1 Partial Release and Satisfaction. 
 (a) On the date on which the Company shall have repaid to the
Secured Party aggregate principal of at least $*** pursuant to the terms and conditions of the Partnership Note, the security interest granted hereunder shall automatically terminate in relation to (i) the United States patents identified on
Schedule C hereto and (ii) the United States patent applications identified on Schedule C hereto and any and all patents that issue with respect thereto (collectively, the “First Released Collateral”) and
all rights to the First Released Collateral shall revert to the Company. 
 (b) Upon such termination, Secured Party shall promptly file or
authorize the Company to file, at the Company’s expense, releases and satisfactions of all registrations and/or filings of the security interests in the First Released Collateral granted hereunder and Secured Party will execute and deliver to
the Company any additional documents or instruments as the Company shall reasonably request to evidence such partial release and satisfaction. 
 3.2 Complete Release and Satisfaction. Upon the termination of this Agreement, the Secured Party shall promptly file or authorize the Company to file, at the Company’s expense, releases and satisfactions of all registrations
and/or filings of the security interests granted hereunder and Secured Party will execute and deliver to the Company any additional documents or instruments as the Company shall reasonably request to evidence such complete release and
satisfaction.” 
 2.3. Section 4.1 of the Agreement shall be amended and restated to read in its entirety as follows: 

“4.1 The Company owns all of the Collateral free and clear of any lien, encumbrance, mortgage, security agreement, pledge or charge other than:
(a) a license and development agreement, dated as of November 26, 2002, by and between the Company and Upsher-Smith Laboratories, Inc. (“USL”); (b) a license agreement, dated as of April 7, 2004, by
and between the Company and Novartis Pharma AG (“Novartis”); and (c) a license agreement, dated as of April 13, 2002, by and between the 
  

 - 3 - 

 Company and SmithKline Beecham Corporation (“GSK”), pursuant to which the
Company has licensed to each of these parties, respectively, the right to use the patents listed on Schedule D hereto.” 
 2.4.
Section 10 of the Agreement shall be amended and restated to read in its entirety as follows: 
 “10. Termination. This
Agreement shall terminate at such time as all of the Obligations shall have been indefeasibly fully paid and satisfied and, until such time, but subject to Section 3.1 of this Agreement, the Secured Party shall retain all security in the
Collateral held by it hereunder.” 
 3. Acknowledgement of Parties. The Company acknowledges that, although Secured Party was not a party
to the original Agreement, the First Amendment and/or the Second Amendment, by virtue of the Assignment Secured Party has been assigned the rights and has assumed the obligations arising under the Agreement and it is appropriate that the Company
shall enter into this Third Amendment with Secured Party (as identified in the opening paragraph of this Third Amendment). 
 4. No Other Changes.
Except as expressly amended hereby, all of the terms and conditions of the Agreement remain in full force and effect. All references in the Agreement (and in the other agreements, documents and instruments entered into in connection therewith) to
the “Agreement” shall be deemed for all purposes to refer to the Agreement, as amended by the First Amendment, the Second Amendment and this Third Amendment. 
 5. Perfection of Security Interest by Filing. The Company and Secured Party hereby agree that in connection with, and contemporaneously with the execution of, this Third Amendment, the Company and Secured Party
shall execute the agreement attached hereto as Exhibit A (which list of patents and patent applications on Exhibit A hereto replaces in its entirety Exhibit A to the Second Amendment), which the Company shall then promptly file
and record, at the Company’s expense, with the U.S. Patent Trademark Office. The Company also hereby authorizes Secured Party to prepare and file such financing statements (including continuation statements) or amendments thereof or supplements
thereto or other instruments as Secured Party may from time to time deem necessary or appropriate in order to perfect and maintain the security interests granted hereunder in accordance with the Uniform Commercial Code as in effect in the State of
New Jersey from time to time. 
 6. Applicable Law. This Amendment shall be construed in accordance with and governed by the laws of the State of New
Jersey without giving effect to conflicts of laws principles. 
 7. Counterparts. This Amendment may be executed in two or more counterparts, each of
which shall be deemed an original and all of which shall constitute one instrument, and such counterparts may be delivered by facsimile or by electronic mail in “portable document format” (or “.pdf”), with any such counterpart
delivered in such way deemed an original. 
  

 - 4 - 

 [Signature page follows] 
  

 - 5 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to be executed on the day
and year first above written. 
  

			
	UNIGENE LABORATORIES, INC.
		
	By:	 	 /s/ William Steinhauer

	Name:	 	William Steinhauer
	Title:	 	Vice President of Finance
	
	JAYNJEAN LEVY FAMILY LIMITED PARTNERSHIP
		
	By:	 	Ronald S. Levy,
		 	Its general partner
		
		 	 /s/ Ronald S. Levy

		 	RONALD S. LEVY
		
	By:	 	Warren P. Levy,
		 	Its general partner
		
		 	 /s/ Warren P. Levy

		 	WARREN P. LEVY

 Schedule A 
 Promissory Notes Assigned to Jaynjean Levy Family Limited Partnership 
  

						
	 	  	Date	  	 Original Principal
Amount (Not
 Amounts Currently
 Outstanding)

	 1
	  	03/13/01	  	$	300,000
	 2
	  	03/27/01	  	 	200,000
	 3
	  	04/09/01	  	 	350,000
	 4
	  	04/16/01	  	 	100,000
	 5
	  	04/23/01	  	 	400,000
	 6
	  	05/09/01	  	 	250,000
	 7
	  	05/29/01	  	 	300,000
	 8
	  	06/11/01	  	 	175,000
	 9
	  	06/19/01	  	 	275,000
	 10
	  	06/28/01	  	 	100,000
	 11
	  	07/05/01	  	 	275,000
	 12
	  	07/26/01	  	 	250,000
	 13
	  	08/13/01	  	 	200,000
	 14
	  	08/29/01	  	 	200,000
	 15
	  	09/13/01	  	 	300,000
	 16
	  	09/26/01	  	 	250,000
	 17
	  	10/11/01	  	 	200,000
	 18
	  	10/29/01	  	 	175,000
	 19
	  	11/13/01	  	 	175,000
	 20
	  	11/28/01	  	 	175,000
	 21
	  	12/12/01	  	 	175,000
	 22
	  	12/19/01	  	 	175,000
	 23
	  	02/13/02	  	 	175,000
	 24
	  	02/26/02	  	 	175,000
	 25
	  	03/13/02	  	 	175,000
	 26
	  	03/26/02	  	 	175,000
		  		  	 	 
		  	Total Principal:	  	$	5,700,000
		  		  	 	 

 Schedule B 
 Outstanding Promissory Notes After Repayment to be Consolidated into the Partnership Note 
  

						
	 	  	Date	  	Currently
Outstanding
Principal Amount1
	 1
	  	03/13/01	  	$	300,000
	 2
	  	03/27/01	  	 	200,000
	 3
	  	04/09/01	  	 	350,000
	 4
	  	04/16/01	  	 	100,000
	 5
	  	04/23/01	  	 	0
	 6
	  	05/09/01	  	 	250,000
	 7
	  	05/29/01	  	 	300,000
	 8
	  	06/11/01	  	 	175,000
	 9
	  	06/19/01	  	 	275,000
	 10
	  	06/28/01	  	 	100,000
	 11
	  	07/05/01	  	 	275,000
	 12
	  	07/26/01	  	 	250,000
	 13
	  	08/13/01	  	 	200,000
	 14
	  	08/29/01	  	 	200,000
	 15
	  	09/13/01	  	 	300,000
	 16
	  	09/26/01	  	 	250,000
	 17
	  	10/11/01	  	 	200,000
	 18
	  	10/29/01	  	 	175,000
	 19
	  	11/13/01	  	 	175,000
	 20
	  	11/28/01	  	 	175,000
	 21
	  	12/11/01	  	 	175,000
	 22
	  	12/19/01	  	 	175,000
	 23
	  	02/13/02	  	 	175,000
	 24
	  	02/26/02	  	 	175,000
	 25
	  	03/13/02	  	 	175,000
	 26
	  	03/26/02	  	 	175,000
		  		  	 	 
		  	Total:	  	 	5,300,000
		  		  	 	 

	 1
	 Even though one of the notes
listed above has no outstanding principal amount due and owing, it is listed because interest has accrued and continues to accrue and to be payable thereunder and such interest amounts are being consolidated into the Partnership Note.

 Schedule C 
 First Released Collateral 
  

					
	 Patent #
	  	 Title
	  	 Date of Patent

	***	  	***	  	***

 Schedule D 
 License Rights to the Collateral 
  

									
	 Name
	 	 US Patent #/
 US Patent Application #
	 	 GSK
	 	 Novartis
	 	 USL

	 ***
	 	***	 	***	 	***	 	***

 EXHIBIT A 
 NOTICE 
 OF 
 GRANT OF SECURITY INTEREST 
 IN 
 PATENTS 
 United States Patent and Trademark Office 
 Ladies and Gentlemen: 
 Please be advised that pursuant to that certain Patent Security Agreement, dated as
of March 13, 2001 (as amended, restated, modified or otherwise supplemented from time to time, the “Security Agreement”), by and between Unigene Laboratories, Inc., a Delaware corporation (the
“Company”), and Jay Levy, a resident of New Jersey (“Levy”), the Company granted a continuing security interest in, and continuing lien upon, certain patents and patent applications to, and for the
ratable benefit of, Levy. Subsequently, upon Levy’s assignment on February 15, 2005 of certain promissory notes to Jaynjean Levy Family Limited Partnership, a Delaware limited partnership (the “Secured Party”),
Levy’s interests pursuant to the Security Agreement were, in accordance with Section 11 of the Security Agreement, assigned to, and assumed by, Secured Party. Notwithstanding the foregoing, pursuant to the Third Amendment to Patent
Security Agreement, dated as of May 10, 2007, by and between the Company and the Secured Party, the undersigned Company has continued its grant of the security interest in, and the lien upon, the patents and patent applications shown below to,
and for the ratable benefit of, the Secured Party: 
 PATENTS 
  

					
	 Patent No.
	 	 Description of Patent
	 	 Date of Patent

	US 6,319,685	 	Alpha-Amidation Enzyme (Protein Interference)	 	November 20, 2001
	US 5,789,234	 	Expression Systems for Amidating Enzyme	 	August 4, 1998
	US 5,912,014	 	Oral Salmon Calcitonin Pharmaceutical Products	 	June 15, 1999
	US 6,086,918	 	Oral Peptide Pharmaceutical Products	 	July 11, 2000

					
	 Patent No.
	 	 Description of Patent
	 	 Date of Patent

	US 6,103,495	 	Direct Expression of Peptides into Culture Media (Divisional 1)	 	August 15, 2000
	US 6,210,925	 	Direct Expression of Peptides into Culture Media (Divisional 2)	 	April 3, 2001
	US 6,440,392	 	Nasal Calcitonin Formulations	 	August 27, 2002
	US 6,627,438	 	Direct Expression of Peptides into Culture Media (Divisional 3)	 	September 3, 2003
	US 6,737,250	 	Direct Expression of Peptides into Culture Media (Divisional 4)	 	May 18, 2004
	US 6,673,524	 	Oral Peptide Pharmaceutical Products	 	January 6, 2004

 PATENT APPLICATIONS 
  

					
	 Patent Application No.
	 	 Description of Patent Applied For
	 	 Date of Patent Application

	Application #10/094,306	 	Oral Peptide Pharmaceutical Dosage Form and Method of Production	 	Filing Date: March 7, 2002

 [no more text on this page] 
  

 - 2 - 

 The Company and the Secured Party hereby acknowledge and agree that the security interest in the
foregoing patents and patent applications (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any patent or patent application. 
  

			
	 Very truly yours,

	
	UNIGENE LABORATORIES, INC.
		
	By:	 	  

	Name:	 	William Steinhauer
	Title:	 	Vice President of Finance

 Acknowledged and Accepted: 
 JAYNJEAN LEVY FAMILY LIMITED PARTNERSHIP 
  

			
		
	By:	 	Ronald S. Levy,
		 	Its general partner
		
		 	  

		 	RONALD S. LEVY
		
	By:	 	Warren P. Levy,
		 	Its general partner
		
		 	  

		 	WARREN P. LEVY

  

 - 3 -Modification of Mortgage and Security Agreement

 Exhibit 10.5 
 Portions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 406 under the Securities Act of 1933. Such
omissions are designated as ***. 
 MODIFICATION OF MORTGAGE AND SECURITY AGREEMENT 
 This Modification of Mortgage and Security Agreement (“Modification”) made effective as of the 10th day of May, 2007, by and
between UNIGENE LABORATORIES, INC., a Delaware corporation authorized to do business in New Jersey, having offices at 110 Little Falls Road, Fairfield, New Jersey 07004 (the “Mortgagor”), and JAY LEVY, with an address at 2150
Center Avenue, Fort Lee, New Jersey 07024 (the “Mortgagee”). 
 WHEREAS, on July 13, 1999, Mortgagee provided a
loan to Mortgagor in the principal amount of ONE MILLION, SIX HUNDRED THOUSAND and 00/100 ($1,600,000.00) DOLLARS (the “Loan”) as evidenced by a certain Amended and Restated Secured Note dated July 13, 1999 (the
“Note”); 
 WHEREAS, in connection with the Loan, Mortgagor executed and delivered a Mortgage and Security Agreement,
dated July 13, 1999, to Mortgagee (the “Original Mortgage”), with respect to property located in the Township of Fairfield, County of Essex and State of New Jersey, as more particularly described in the Original Mortgage
(the “Premises”), which Original Mortgage was recorded in the Essex County Register’s Office; 
 WHEREAS,
Mortgagee provided additional loans to Mortgagor evidenced by a Secured Note dated July 30, 1999 (the “7/30/99 Note”) in the amount of SEVENTY THOUSAND and 

 
00/100 ($70,000.00) DOLLARS and a Secured Note dated August 5, 1999 (the “8/5/99 Note”) in the amount of TWO HUNDRED THOUSAND
and 00/100 ($200,000.00) DOLLARS made by Mortgagor to Mortgagee (together, the “Additional Loans”); 
 WHEREAS, as a
condition of the Additional Loans, Mortgagee required that Mortgagor amend the Original Mortgage to secure the 7/30/99 Note and the 8/5/99 Note (together, the “Additional Notes” and together with the Note, collectively, the
“Notes”) and in connection therewith, Mortgagor executed and delivered a Modification of Mortgage and Security Agreement to Mortgagee dated August 5, 1999 (the “First Modification”), which was
recorded in the Essex County Register’s Office with respect to the Premises; 
 WHEREAS, on the date of execution hereof, Mortgagor is
repaying some of the outstanding amounts due and owing to Mortgagee, and in connection therewith, and in consideration of such repayment, Mortgagor is (i) restructuring the Notes and the remaining outstanding promissory notes that Mortgagor has
issued to Mortgagee, as detailed on Schedule A hereto (collectively, the “Other Notes”), and (ii) consolidating the Notes and the Other Notes into one amended and restated Secured Note (the “New
Note”), dated as of the date of execution hereof, in the principal amount of EIGHT MILLION, THREE HUNDRED EIGHTEEN THOUSAND, SEVEN HUNDRED FOURTEEN and 00/100 DOLLARS ($8,318,714.00); 
 WHEREAS, as a condition to the execution and delivery of the New Note, Mortgagee is requiring that Mortgagor amend the Original Mortgage, as modified by
the First Modification (the “Amended Mortgage”), to secure the New Note instead of the Notes and in connection therewith, the Company is entering into this Modification to further amend the Amended Mortgage; and 

 

 - 2 - 

 WHEREAS, upon the execution and filing of this Modification, the Notes shall not be subject to the
Amended Mortgage and instead the New Note shall be subject to the Amended Mortgage, as further amended by this Modification (the “Mortgage”); provided, that Mortgagee and Mortgagor each agree that neither the New Note
or the Mortgage represents, evidences or documents a novation of the Notes, but rather represents, evidences and documents the continuation of all obligations and liabilities of every kind and nature of Mortgagor outstanding thereunder that exist as
of the date hereof, as more fully described herein and therein. 
 NOW, THEREFORE, the parties agree as follows: 
 1. Modification of Mortgage. The Mortgage shall be deemed modified to secure the Additional Loans as evidenced by the New Note dated as of the
date of execution hereof in the principal amount of Eight Million, Three Hundred Eighteen Thousand, Seven Hundred Fourteen and 00/100 Dollars ($8,318,714.00), and accordingly the total amount due Mortgagee by Mortgagor and secured by the Mortgage as
hereby amended shall be the principal amount of Eight Million, Three Hundred Eighteen Thousand, Seven Hundred Fourteen and 00/100 Dollars ($8,318,714.00). 
 2. Release of Mortgage. On the date on which Mortgagor shall have repaid to Mortgagee aggregate principal of at least $*** pursuant to the terms and conditions of the New Note, (i) the New Note shall no
longer be subject to this Mortgage, (ii) this Mortgage shall 

  

 - 3 - 

 
automatically terminate and (iii) all rights to the Premises shall revert to Mortgagor. Thereupon, Mortgagee shall promptly file, or execute and deliver
to Mortgagor and authorize Mortgagor to file, at Mortgagor’s expense, releases and satisfactions of all recordations and/or filings of the Mortgagee’s security interests in the Premises granted hereunder and Mortgagee will execute and
deliver to Mortgagor any additional documents or instruments as Mortgagor shall reasonably request to evidence such release and satisfaction. 
 3. Mortgagor’s Estoppel. Mortgagor does hereby represent, warrant and confirm that there are no set-offs, rights, claims or causes of action of any nature whatsoever which Mortgagor has or may assert against Mortgagee with
respect to the Mortgage and the indebtedness secured thereby as aforesaid. 
 4. Affirmation of Validity of Loan Documents. Mortgagor
does hereby affirm the extent and validity of the Mortgage and the New Note secured thereby, and does confirm that all loan documentation (with the exception of the Notes) remains enforceable, and in full force and effect as of the date of execution
hereof, and that the Mortgage, as modified by the within agreement, shall constitute a continuing, valid lien upon the Premises, to secure payment of the indebtedness evidenced by the New Note as aforesaid. 
 5. Binding Effect. The within agreement shall be binding upon the parties hereto, their successors and assigns. 
 6. Governing Law. The within agreement shall be construed and enforced in accordance with the laws of the State of New Jersey. 
  

 - 4 - 

 7. Copy Acknowledge. The undersigned Mortgagor acknowledges receipt of a true copy of this
document without charge. 
 [no more text on this page] 
  

 - 5 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Modification of Mortgage and Security Agreement
as of the day and year first above written. 
  

									
	Attest:	 		 	Unigene Laboratories, Inc.
					
	  	 	/s/ Ronald Levy	 		 	By:	 	/s/ William Steinhauer
	Ronald S. Levy, Secretary	 		 		 	William Steinhauer, Vice President of Finance

 Witness: /s/ Lynn Rogalny 

 Schedule A 
 Outstanding Promissory Notes After Repayment 
 to be
Consolidated into the New Note1 
  

													
	 	  	 Date
	  	Currently
Outstanding
Principal Amount2	  	 	  	Date	  	Currently
Outstanding
Principal
Amount2
	1	  	03/02/95	  	$	 0	  	1B	  	07/13/99	  	$	1,525,000
	2	  	06/29/95	  	 	0	  	2B	  	07/30/99	  	 	70,000
	3	  	11/22/99	  	 	0	  	3B	  	08/05/99	  	 	200,000
	4	  	02/11/00	  	 	0	  		  	Total:	  	 	1,795,000
	5	  	11/13/00	  	 	0	  		  		  		
	6	  	11/16/00	  	 	0	  		  		  		
	7	  	01/09/01	  	 	0	  	1C	  	02/10/95	  	$	0
	8	  	01/16/01	  	 	0	  	2C	  	07/12/00	  	 	0
	9	  	02/05/01	  	 	0	  	3C	  	07/31/00	  	 	0
	10	  	02/13/01	  	 	0	  	4C	  	08/11/00	  	 	0
	11	  	02/22/01	  	 	0	  	5C	  	08/30/00	  	 	0
		  	Total:	  	 	0	  	6C	  	09/13/00	  	 	0
		  		  			  	7C	  	09/27/00	  	 	0
		  		  			  		  	Total:	  	 	0

  

	 1
	 Also outstanding and included in the consolidation into the New Note but not listed here is a 5% penalty
on overdue amounts on certain notes which were originally payable to Jean Levy, plus accrued interest, which began accruing on 01/01/01. 

  

	 2
	 Even though certain notes listed
above have no outstanding principal amount due and owing, they are listed because interest has accrued and continues to accrue and to be payable thereunder and such interest amounts are being consolidated into the New Note.

					
	STATE OF NEW JERSEY	  	)	  	
		  	)	  	ss:
	COUNTY OF ESSEX	  	)	  	

 I certify that on May 10, 2007, Ronald S. Levy personally came before me and this person
acknowledged under oath, to my satisfaction, that: 
  

	 	(a)	this person is the Secretary of Unigene Laboratories, Inc., the corporation named in this document; 

  

	 	(b)	this person is the attesting witness to the signing of this document by the proper corporate officer who is William Steinhauer, the Vice President of Finance of the corporation;

  

	 	(c)	this document was signed and delivered by the corporation as its voluntary act duly authorized by a proper resolution of its Board of Directors; 

  

	 	(d)	this person knows the proper seal of the corporation which was affixed to this document; and 

  

	 	(e)	this person signed this proof to attest to the truth of these facts. 

 Sworn and Subscribed to this 
 10th day of May, 2007 
 /s/ Linda Rohloff 
 Notary Information: 
 Linda Rohloff 
 State of New Jersey, Passaic County 
 #2057307 
 Expires 4/11/09

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]